Maggie L. Shaw

Jeff Hunnicutt, CEO of Highlands Oncology Group, explains the 2 risk options provided under the Enhancing Oncology Model (EOM) and why the mandatory downside risk might give pause to practices that saw some success in the Oncology Care Model.

As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR has evolved from the initial discovery of the double helix to now, with the technology holding great promise for both genetic diseases and cancers.

Andre Harvin, PharmD, MS, MBA, Cone Health Cancer Center, discusses the vital role of pharmacists in oncology: how they use data to streamline patient visits, work to facilitate patient access to biosimilars, and advocate for their patients.

The supplemental Biologics License Application was filed for the new indication for dupilumab, which is already approved to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.

Olalekan Ajayi, PharmD, MBA, chief operating officer of Highlands Oncology Group, PA, and 2023-2024 president-elect of the Association of Community Cancer Centers (ACCC), discusses why he is excited for this year’s meeting, including its many workshops and day 1 keynote on CRISPR.

Carolina Blood and Cancer Care Associates’ No One Left Alone initiative works to dismantle cancer health disparities and increase health care equity among its rural patient population. Sashi Naidu, MD, director of research, discusses delivering next-generation sequencing testing to patients.

Potential disparities in care highlight the great need for tailored cardiovascular health (CVH) interventions among bisexual female individuals, according to a recent study.

The 2 therapies, a 1-food and a 6-food elimination diet both used for eosinophilic esophagitis (EoE), were compared for outcomes after 6 weeks.

Deepak L. Bhatt, MD, MPH, Icahn School of Medicine at Mount Sinai, has multiple presentations during the upcoming American College of Cardiology Scientific Sessions, including additional phase 2 results from the ENTRIGUE trial for pegozafermin in severe hypertriglyceridemia. 

Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discusses the present state of value-based oncology care and what the future may bring when the Enhancing Oncology Model kicks off on July 1.

Study results presented at this year’s American Academy of Allergy Asthma & Immunology annual meeting displayed dupilumab efficacy in children aged 6 months to 5 years who had atopic dermatitis (AD).

Outcomes from the loop diuretics were compared in this analysis, with study participants from the TRANSFORM-HF trial matched 1:1, all having been hospitalized for either do novo disease or worsening chronic disease.

David A. Eagle, MD, New York Cancer & Blood Specialists, discusses the present state of treatment for cancer, which often sees patient financial concerns outweighed by the cost of treatment.

In this analysis, evidence was reviewed for the effectiveness of intranasal corticosteroids, biologics, and aspirin therapy after desensitization use among patients who have chronic rhinosinusitis with nasal polyposis (CRSwNP).

Tochi M. Okwuosa, DO, Rush University Medical Center, discusses ways in which cancer treatments can adversely affect heart health outcomes for patients under the care of oncologists.

Investigators compared these outcomes due to limited research in the space, with previous surveys suggesting care disparities.

On this episode of Managed Care Cast, we speak with Simon F. Haeder, PhD, MPA, professor of public health at the Texas A&M University School of Public Health. He and his co-investigators looked at the accuracy of directories of psychiatrists and nonphysician mental health providers for all plans regulated by the California Department of Managed Health Care in 2018 and 2019.

We’ve found through health equity initiatives that the search for the right telehealth modality is never ending, explained Oncology Consultants of Houston’s Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy.

This review and meta-analysis included 34 studies covering 1762 patients, and investigated the efficacy of 4 varieties of dietary treatment for eosinophilic esophagitis (EoE).

At Carolina Blood and Cancer Care Associates, the No One Left Alone (NOLA) initiative is working to break down cancer health disparities among its patients by addressing the social determinants of health that may be preventing equitable access to care.

This study investigated the impact atopic dermatitis (AD) has on out-of-pocket (OOP) costs for caregivers of pediatric patients with the chronic skin condition.

Implications of these findings include a more clear understanding of the burden imposed by heart failure (HF), which encompasses the cost of care and adverse health outcomes.

This exploration of eczema self-management investigated the potential effectiveness of 2 online behavioral interventions, 1 each for young patients and their parents and/or caregivers.

The authors conducted a subanalysis of data on 100,000-plus children from 3 studies to estimate the global prevalence and severity of eczema; they used linear mixed models to do so.

On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.

Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.

Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical, discusses the multidisciplinary process that underlies caring for patients with cancer who may develop heart damage.

With atopic dermatitis (AD) prevalence increasing around the world, primarily in developing countries, investigators evaluated the potential for pollution to have an impact on development of the chronic skin condition among an adult population.